Prevention of de novo HCV with Antiviral HCV Therapy Post- liver and Post-kidney Transplant, Virologic Failure Sub-study
Prevention of Hepatitis C with Antiviral HCV Therapy After Liver and/or Kidney Transplant
Sponsor: University of California, San Francisco
Enrolling: Male and Female Patients
IRB Number: AAAR8005
U.S. Govt. ID: NCT03619837
Contact: Elizabeth Verna, MD: 212-305-3839 /
Additional Study Information: In this study, patients who are listed for a kidney or a liver transplant may be eligible for enrollment, asdetermined by their transplant doctors. The study is looking at patients who do not have hepatitis C virus (HCV) and provide their informed consent to receive a liver or kidney from a HCV positive donor. FDA approved medications that are used to treat HCV will be given to the study subjects shortly aftertransplant to protect them from developing the problems HCV can cause to the liver. This research study is being done to learn whether organ transplantation of livers and kidneys from donors who have HCV is safe and effective in recipients that do not have HCV.
This study is closed
Elizabeth Verna, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Are you waitlisted for kidney or liver transplant? Yes No
Are you infected with Hepatitis C Virus (HCV)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Elizabeth Verna, MD